Viking Therapeutics Inc share price logo

Viking Therapeutics Inc

NASDAQ: VKTX

Mid Cap

$31.76

+1.76

(+5.87%)

as on

Viking Therapeutics Inc Stock Performance

as on May 5, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $29.65
    $32.42
    downward going graph

    6.64%

    Downside

    2.08%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $22.96
    $43.15
    downward going graph

    27.71%

    Downside

    35.86%

    Upside

    downward going graph

Viking Therapeutics Inc share price movements today

Previous Close
$30.00
Open
$30.23
Volume
3.0M
Day's Low - High
$29.65 - $32.42
52 Week Low - High
$22.96 - $43.15

Viking Therapeutics Inc Historical Returns

1 Month Return
-13.79 %
3 Month Return
+ 14.11 %
1 Year Return
+ 1.73 %
3 Year Return
+ 31.23 %
5 Year Return
+ 405.05 %

Viking Therapeutics Inc Stock Fundamentals & Key Indicators

Check Viking Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.5B

EPS (TTM)

-4.3378

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-0.03

EBITDA

-

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-70.04%

Viking Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Viking Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$3.5B405.05%NA0.00%
BUY$39.5B123.19%74.5912.55%
BUY$107.8B98.21%27.7132.94%
NA$32.7BNA118.975.37%
BUY$73.5B45.4%17.1229.65%

Stock Returns calculator for Viking Therapeutics Inc Stock including INR - Dollar returns

The Viking Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Viking Therapeutics Inc investment value today

Current value as on today

₹1,21,461

Returns

₹21,461

(+21.46%)

Returns from Viking Therapeutics Inc Stock

₹7,698 (+7.7%)

Dollar Impact

₹13,763 (+13.76%)

Analyst Recommendation on Viking Therapeutics Inc Stock

Based on 17 analysts

BUY

94.12%

Buy

5.88%

Hold

0.00%

Sell

Based on 17 analysts, 94.12% of analysts recommend a 'BUY' rating for Viking Therapeutics Inc. Average target price of $92.44

Viking Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Viking Therapeutics Inc.

What analysts predicted

65.64%UPSIDE

Target Price

$92.44

Current Price

$31.76

Analyzed by

17 Analysts

Target

$92.44

Viking Therapeutics Inc target price $92.44, a slight upside of 65.64% compared to current price of $31.76. According to 17 analysts rating.

Viking Therapeutics Inc Stock’s Investor Sentiment and Interest

Investment in Viking Therapeutics Inc Shares on INDmoney has grown by 49.66% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:49.66% versus previous 30 day period

Search interest for Viking Therapeutics Inc Stock has increased by 23% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:23% versus previous 30 day period

Viking Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
-
0
0
0
-
Operating Income
-29
-34
-34
-36
-46
-55
-74
-98
-164
-164
EBITDA
-29
-33
-33
-36
-46
-55
-74
-98
-164
-164
Interest Expense
0
0
0
0
0
0
0
0
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-24
-27
-22
-24
-35
-45
-65
-90
-157
-158
Income Tax Expense
1
0
-
0
-
-
-
-
-
-
Net Income
-24
-27
-22
-24
-35
-45
-65
-90
-157
-158
Net Profit Margin
-5643.35%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Viking Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
0
0
-
-
-
-
Gross Profit
-
-
-
0
0
0
0
0
0
0
Operating Income
-13
-19
-26
-32
-42
-55
-70
-100
-150
-393
EBITDA
1
0
4
-25
3
-55
-70
-100
-150
-393
Interest Expense
2
1
0
0
0
0
0
0
0
0
Depreciation
-
-
-
0
0
0
0
0
0
0
Income Before Tax
-14
-20
-22
-25
-39
-54
-68
-85
-109
-359
Income Tax Expense
1
1
-2
6
-3
0
-1
0
-109
-
Net Income
-14
-20
-22
-25
-39
-54
-68
-85
-109
-359
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
-368045.85%
-513877.21%
0.00%
0.00%
0.00%
0.00%

Viking Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-27
-22
-24
-35
-45
-65
-90
-157
-158
Operating Cash Flow
-6
-28
-21
-31
-52
-47
-94
-85
-113
Investing Cash Flow
-459
-126
25
6
63
42
160
75
54
Financing Cash Flow
606
2
2
1
0
0
0
75
12
Change in Cash
140
-151
6
-23
11
-4
66
65
-47

Viking Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-20
-22
-25
-39
-54
-68
-85
-109
-359
Operating Cash Flow
-14
-18
-24
-21
-47
-48
-73
-87
-278
Investing Cash Flow
-1
-265
7
41
37
54
-179
-553
341
Financing Cash Flow
22
300
0
0
6
4
271
612
76
Change in Cash
5
15
-16
20
-2
10
18
-28
139

Global Institutional Holdings in Viking Therapeutics Inc

Funds
Holdings
State Street Corp
3.89%
FMR Inc
5.66%
NORGES BANK
1.57%
Morgan Stanley - Brokerage Accounts
3.22%
Morgan Stanley - Brokerage Accounts
2.65%

Viking Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 12 February

    Thu, 06:14 PM

    -

    Viking Therapeutics jumps 16% after announcing Phase 3 development plans for its oral obesity drug and reporting a wider loss.

    Thu, 06:33 PM

    -

    Viking reports a fourth-quarter loss of $1.38 per share, wider than expected, while advancing its oral obesity drug into late-stage development.

    Thu, 11:17 PM

    -

    Viking Therapeutics shares rise 8% following the announcement of advancing its oral obesity drug into Phase 3 development.

Insights on Viking Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, VKTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 16.2% return, outperforming this stock by 14.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, VKTX stock has moved down by -7.4%

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
OrganisationViking Therapeutics Inc
Headquarters9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
IndustryBiotechnology
CEODr. Brian Lian Ph.D.
E-voting on sharesClick here to vote

Key Management of Viking Therapeutics Inc

Name

Title

Mr. Michael Morneau

Vice President of Finance & Administration

Mr. Kenneth J. Herman M.B.A.

Senior Vice President of Commercial, Marketing & Sales

Dr. Geoffrey E. Barker Ph.D.

Chief Development Officer

Mr. Neil Aubuchon B.A., M.B.A.

Chief Commercial Officer

Dr. Nils U. Olsson Ph.D.

Senior Vice President of Technical Operations

Dr. Brian Lian Ph.D.

President, CEO & Director

Mr. Gregory S. Zante CPA

Chief Financial Officer

Ms. Marianne Mancini

Chief Operating Officer

Ms. Katherine Mercier

Vice President of Quality and Compliance

FAQs

What is Viking Therapeutics Inc share price today?

Viking Therapeutics Inc share price today is $31.76 as on at the close of the market. Viking Therapeutics Inc share today touched a day high of $32.42 and a low of $29.65.

What is the 52 week high and 52 week low for Viking Therapeutics Inc share?

Viking Therapeutics Inc share touched a 52 week high of $43.15 on and a 52 week low of $22.96 on . Viking Therapeutics Inc stock price today i.e. is closed at $31.76,which is 26.40% down from its 52 week high and 38.33% up from its 52 week low.

What is Viking Therapeutics Inc's market capitalisation today?

Viking Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Viking Therapeutics Inc Stock (VKTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Viking Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viking Therapeutics Inc Shares that will get you 0.0472 shares as per Viking Therapeutics Inc share price of $31.76 per share as on May 5, 2026 at 1:29 am IST.

What is the minimum amount required to buy Viking Therapeutics Inc Stock (VKTX) from India?

Indian investors can start investing in Viking Therapeutics Inc (VKTX) shares with as little as ₹95.067 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹950.67 in Viking Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Viking Therapeutics Inc share’s latest price of $31.76 as on May 5, 2026 at 1:29 am IST, you will get 0.3149 shares of Viking Therapeutics Inc. Learn more about fractional shares .

What are the returns that Viking Therapeutics Inc has given to Indian investors in the last 5 years?

Viking Therapeutics Inc stock has given 405.05% share price returns and 28.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?